Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17834055 | 1.00 | LMNA (0.33) | LMNACYP2C9TSHRANPEPCNR2 | |
| SCHEMBL4843667 | 1.00 | LMNA (0.33) | LMNACYP2C9TSHRANPEPCNR2 | |
| SCHEMBL21038564 | 1.00 | LMNA (0.33) | LMNACYP2C9TSHRANPEPCNR2 | |
| SCHEMBL17834053 | 1.00 | LMNA (0.33) | LMNACYP2C9TSHRANPEPCNR2 | |
| SCHEMBL4835227 | 0.96 | TSHR (0.38) | LMNACYP2C9TSHRDPP4 | |
| SCHEMBL4845201 | 0.94 | TSHR (0.36) | LMNACYP2C9TSHR | |
| SCHEMBL4844966 | 0.86 | TSHR (0.41) | TSHR | |
| SCHEMBL102291 | 0.86 | LMNA (0.36) | LMNACYP2C9 | |
| SCHEMBL14652016 | 0.86 | LMNA (0.36) | LMNACYP2C9 | |
| SCHEMBL10974716 | 0.84 | ANPEP (0.32) | ANPEPDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | Epizyme, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | LMNA 2503/4885CYP2C9 4700/4885TSHR 3589/4885 |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | LMNA 2503/4885CYP2C9 4700/4885TSHR 3589/4885 |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | EP300, KAT2A, KAT6A | LMNA 2503/4885CYP2C9 4700/4885TSHR 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.